

Application of

: Himmelsbach, F. et al

) Art Unit:

FEB 0 1 2002 1624

Serial No.

: 09/934,631

) Examiner:

TECH CENTER 1600/2900

Confirmation No.: 8655

Filed

: 08/22/2001 V

For

: Aminoquinazolines Which Inhibit Signal Transduction Mediated By

Tyrosine Kinases

Docket No.

: 5/1303

Commissioner for Patents Washington, D.C. 20231

January 23, 2002

## TRANSMITTAL LETTER FOR SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Transmitted herewith concerning the subject application is an Information Disclosure Statement under 37 C.F.R. §§1.56 and

This Statement is being filed within three months of the filing date of a  $\boxtimes$ national application; within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an international application; or before the mailing of a first Office Action on the merits, whichever event occurs last.

The Assistant Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. §1.16 and any patent application processing fees under 37 C.F.R. §1.17, or credit any overpayment of same, to Deposit Account No. 02-2955.

Triplicate copies of this form are enclosed.

Respectfully submitted,

Alan R. Stempel

Attorney for Applicant(s)

Reg. No. 28,991

Patent Department Boehringer Ingelheim Corp. 900 Ridgebury Road, P.O. Box 368

Ridgefield, CT. 06877 Tel.: (203) 798-4868

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents Washington, DC 20231

on January 23, 2002

Alan R. Stempel, Reg By: